These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 11692054)

  • 1. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy.
    Campbell S; Ghosh S
    Eur J Gastroenterol Hepatol; 2001 Nov; 13(11):1297-301. PubMed ID: 11692054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is neutropenia required for effective maintenance of remission during azathioprine therapy in inflammatory bowel disease?
    Campbell S; Ghosh S
    Eur J Gastroenterol Hepatol; 2001 Sep; 13(9):1073-6. PubMed ID: 11564958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
    Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
    Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review.
    Fraser AG; Orchard TR; Jewell DP
    Gut; 2002 Apr; 50(4):485-9. PubMed ID: 11889067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease.
    Mossop H; Davies P; Murphy MS
    J Pediatr Gastroenterol Nutr; 2008 Aug; 47(2):123-9. PubMed ID: 18664861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease.
    Ramakrishna J; Langhans N; Calenda K; Grand RJ; Verhave M
    J Pediatr Gastroenterol Nutr; 1996 Apr; 22(3):296-302. PubMed ID: 8708884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Course of inflammatory bowel disease in patients infected with human immunodeficiency virus.
    Viazis N; Vlachogiannakos J; Georgiou O; Rodias M; Georgiadis D; Papastamopoulos V; Baraboutis IG; Karamanolis DG; Skoutelis A
    Inflamm Bowel Dis; 2010 Mar; 16(3):507-11. PubMed ID: 19714759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug therapy of inflammatory bowel disease.
    Sack DM; Peppercorn MA
    Pharmacotherapy; 1983; 3(3):158-76. PubMed ID: 6136027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease.
    Lee JM; Kim YJ; Lee KM; Yoon H; Lee BI; Kim DB; Kang D
    Scand J Gastroenterol; 2018; 53(10-11):1280-1285. PubMed ID: 30351977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone density improves with disease remission in patients with inflammatory bowel disease.
    Reffitt DM; Meenan J; Sanderson JD; Jugdaohsingh R; Powell JJ; Thompson RP
    Eur J Gastroenterol Hepatol; 2003 Dec; 15(12):1267-73. PubMed ID: 14624148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.
    Stocco G; Cuzzoni E; De Iudicibus S; Favretto D; Malusà N; Martelossi S; Pozzi E; Lionetti P; Ventura A; Decorti G
    World J Gastroenterol; 2015 Mar; 21(12):3571-8. PubMed ID: 25834322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
    Roblin X; Serre-Debeauvais F; Phelip JM; Faucheron JL; Hardy G; Chartier A; Helluwaert F; Bessard G; Bonaz B
    Aliment Pharmacol Ther; 2005 Apr; 21(7):829-39. PubMed ID: 15801918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with the use of low-dose methotrexate for inflammatory bowel disease.
    Soon SY; Ansari A; Yaneza M; Raoof S; Hirst J; Sanderson JD
    Eur J Gastroenterol Hepatol; 2004 Sep; 16(9):921-6. PubMed ID: 15316419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis.
    Mantzaris GJ; Sfakianakis M; Archavlis E; Petraki K; Christidou A; Karagiannidis A; Triadaphyllou G
    Am J Gastroenterol; 2004 Jun; 99(6):1122-8. PubMed ID: 15180735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
    Bonapace CR; Mays DA
    Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A report on efficacy and safety of azathioprine in a group of inflammatory bowel disease patients in northwest Greece.
    Christodoulou D; Katsanos K; Baltayannis G; Tzabouras N; Tsianos EV
    Hepatogastroenterology; 2003; 50(52):1021-4. PubMed ID: 12845970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease.
    Ranjan MK; Vuyyuru SK; Kante B; Kumar P; Mundhra SK; Golla R; Sharma R; Sahni P; Das P; Makharia G; Kedia S; Ahuja V
    Int J Colorectal Dis; 2022 Aug; 37(8):1817-1826. PubMed ID: 35835862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.